Access Pharmaceuticals is an emerging pharmaceutical company that develops polymer-linked cytotoxics for use in the treatment of cancer. Its lead product, AP5346, is in Phase 2 clinical testing. The Company also has other advanced drug delivery technologies, including vitamin-mediated targeted delivery, nonparticle aggregates and oral drug delivery products. Access Pharmaceuticals has headquarters in Dallas and is traded publicly on the American Stock Exchange under the symbol ACCP.
Partial Data by Infogroup (c) 2024. All rights reserved.